Key Takeaways STE's Healthcare unit saw 6% organic growth, fueled by U.S. procedures, pricing and market share gains. STERIS' AST business saw robust growth, aided by EO sterilization and demand from biopharma makers. STE cut long-term debt by 38.5%, ending fiscal Q4 with more cash than short-term debt on the books.STERIS plc’s (STE) Healthcare segment is gaining from the successful market adoption of its comprehensive offering, including infection prevention consumables and capital equipment. The Applied ...

STERIS plc’s (STE) Healthcare business continues to benefit from robust U.S. procedure volumes, favorable pricing and market share gains. Service revenues fuel the Applied Sterilization Technologies (“AST”) segment’s growth. Moreover, sound financial health bodes well for the stock. Meanwhile, macroeconomic challenges and adverse currency impacts appear concerning for the company’s operations. In the past year, shares of this Zacks Rank #3 (Hold) company have advanced 10.4% against the industry’s 10.4% fall ...